By Adam FeuersteinAug. 27, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.The Food and Drug Administration on Thursday approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease characterized by muscle weakness and a painful skin rash.
The drug, called brepocitinib, will be marketed under the brand name Lisraya. It’s a pill taken once daily.
High doses of steroids and other immune-suppressing drugs are the current standard of care for patients with dermatomyositis, which affects between 40,000 and 70,000 people in the U.S., according to Roivant.
